Current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver disease

Cholesterol pseudopolyps are the most common variant of gallbladder polyps (GP). Their development is pathogenetically connected with the components of metabolic syndrome, especially with dislipoproteinemia and nonalcoholic fatty liver disease (NAFLD). Lipid metabolism disorder in the form of increa...

Full description

Bibliographic Details
Main Authors: S. N. Mekhtiev, O. A. Mekhtievа, O. M. Berko
Format: Article
Language:Russian
Published: Remedium Group LLC 2022-08-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/7023
_version_ 1797841903154102272
author S. N. Mekhtiev
O. A. Mekhtievа
O. M. Berko
author_facet S. N. Mekhtiev
O. A. Mekhtievа
O. M. Berko
author_sort S. N. Mekhtiev
collection DOAJ
description Cholesterol pseudopolyps are the most common variant of gallbladder polyps (GP). Their development is pathogenetically connected with the components of metabolic syndrome, especially with dislipoproteinemia and nonalcoholic fatty liver disease (NAFLD). Lipid metabolism disorder in the form of increased levels of total cholesterol, low-density lipoproteins (LDL), decreased high-density lipoproteins (HDL), as well as steatosis and liver inflammation lead to disorders of enterohepatic circulation (EHC) of bile acids, changes in rheological properties of bile, which, eventually, can lead to uptake of excess bile cholesterol by epithelium of GP in form of micelles. Infiltration of microvilli with bile micelles causes activation of tissue macrophages and triggers subclinical microinflammation of GB wall. When neighboring microvilli, crowded with foamy cells, merge, cholesterol pseudopolyp is formed, which represents a focal form of GB cholesterosis. The main drug that influences the recovery of EHC and physicochemical properties of bile is ursodeoxycholic acid (UDCA). There is also evidence that UDCA can improve parameters of lipid metabolism, liver enzymes, reduce the severity of hepatic steatosis. The use of UDCA in patients with polyposis form of GB cholesterosis has demonstrated positive results against cholesterol polyps. Glycyrrhizic acid (GA), which has anti-inflammatory, antioxidant, antifibrotic, and other beneficial properties, can improve the effectiveness of therapy for GB polyps by acting on the subclinical microinflammation component of the GB wall. In a prospective observational study, the use of fixed combination of UDCA with GA in patients with cholesterol polyps of GB and NAFLD for 3 months resulted in reduction of polyp number and size in more than 50% of patients, which was accompanied by significant improvement of lipid spectrum and liver enzymes parameters. Further studies of UDCA+GA combination in the combination of these pathologies are required.
first_indexed 2024-04-09T16:38:59Z
format Article
id doaj.art-5be02f3fbc174a3f8f4305e314765990
institution Directory Open Access Journal
issn 2079-701X
2658-5790
language Russian
last_indexed 2024-04-09T16:38:59Z
publishDate 2022-08-01
publisher Remedium Group LLC
record_format Article
series Медицинский совет
spelling doaj.art-5be02f3fbc174a3f8f4305e3147659902023-04-23T06:56:47ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902022-08-01014707810.21518/2079-701X-2022-16-14-70-786285Current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver diseaseS. N. Mekhtiev0O. A. Mekhtievа1O. M. Berko2Pavlov First Saint Petersburg State Medical University; Gastroenterology Center ExpertPavlov First Saint Petersburg State Medical University; Gastroenterology Center ExpertGastroenterology Center ExpertCholesterol pseudopolyps are the most common variant of gallbladder polyps (GP). Their development is pathogenetically connected with the components of metabolic syndrome, especially with dislipoproteinemia and nonalcoholic fatty liver disease (NAFLD). Lipid metabolism disorder in the form of increased levels of total cholesterol, low-density lipoproteins (LDL), decreased high-density lipoproteins (HDL), as well as steatosis and liver inflammation lead to disorders of enterohepatic circulation (EHC) of bile acids, changes in rheological properties of bile, which, eventually, can lead to uptake of excess bile cholesterol by epithelium of GP in form of micelles. Infiltration of microvilli with bile micelles causes activation of tissue macrophages and triggers subclinical microinflammation of GB wall. When neighboring microvilli, crowded with foamy cells, merge, cholesterol pseudopolyp is formed, which represents a focal form of GB cholesterosis. The main drug that influences the recovery of EHC and physicochemical properties of bile is ursodeoxycholic acid (UDCA). There is also evidence that UDCA can improve parameters of lipid metabolism, liver enzymes, reduce the severity of hepatic steatosis. The use of UDCA in patients with polyposis form of GB cholesterosis has demonstrated positive results against cholesterol polyps. Glycyrrhizic acid (GA), which has anti-inflammatory, antioxidant, antifibrotic, and other beneficial properties, can improve the effectiveness of therapy for GB polyps by acting on the subclinical microinflammation component of the GB wall. In a prospective observational study, the use of fixed combination of UDCA with GA in patients with cholesterol polyps of GB and NAFLD for 3 months resulted in reduction of polyp number and size in more than 50% of patients, which was accompanied by significant improvement of lipid spectrum and liver enzymes parameters. Further studies of UDCA+GA combination in the combination of these pathologies are required.https://www.med-sovet.pro/jour/article/view/7023cholesterol polyps of the gallbladdercholesterosis of the gallbladdernon-alcoholic fatty liver diseasemicroinflammationdyslipoproteidemiaursodeoxycholic acidglycyrrhizic acid
spellingShingle S. N. Mekhtiev
O. A. Mekhtievа
O. M. Berko
Current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver disease
Медицинский совет
cholesterol polyps of the gallbladder
cholesterosis of the gallbladder
non-alcoholic fatty liver disease
microinflammation
dyslipoproteidemia
ursodeoxycholic acid
glycyrrhizic acid
title Current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver disease
title_full Current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver disease
title_fullStr Current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver disease
title_full_unstemmed Current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver disease
title_short Current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver disease
title_sort current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver disease
topic cholesterol polyps of the gallbladder
cholesterosis of the gallbladder
non-alcoholic fatty liver disease
microinflammation
dyslipoproteidemia
ursodeoxycholic acid
glycyrrhizic acid
url https://www.med-sovet.pro/jour/article/view/7023
work_keys_str_mv AT snmekhtiev currentperspectiveontheproblemofcholesterolpolypsofthegallbladderinpatientswithnonalcoholicfattyliverdisease
AT oamekhtieva currentperspectiveontheproblemofcholesterolpolypsofthegallbladderinpatientswithnonalcoholicfattyliverdisease
AT omberko currentperspectiveontheproblemofcholesterolpolypsofthegallbladderinpatientswithnonalcoholicfattyliverdisease